Cyclosporine A induced remission of relapsing nephrotic syndrome in children

A. Tejani, K. Butt, H. Trachtman, Manikkam Suthanthiran, C. J. Rosenthal, M. R. Khawar

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

We treated 20, steroid resistant or steroid dependent and cyclophosphamide or chlorambucil treated, relapsing nephrotic patients with oral cyclosporine A for eight weeks. Cyclosporine A was started at 7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of 20 patients, 14 had a complete remission and the remaining 6 had a reduction in their proteinuria. The mean serum albumin of the 14 responders rose from 2.1 g/dl to 4.1 g/dl (P < 0.00001) after cyclosporine A therapy. The mean serum cholesterol of the 14 responders decreased from 394 mg/dl to 184 mg/dl (P < 0.0001) after cyclosporine A therapy. The mean creatinine clearance of the 20 patients (104 ml/min/1.73 m2) was unchanged (107 ml/min/1.73 m2) after eight weeks of cyclosporine A. By life table analysis, 40% of the responders show a sustained remission of up to a year. Cyclosporine A responders had a higher T3 cell count prior to therapy compared to nonresponders (69 ± 5.54% vs. 61 ± 6.4%, P < 0.02). Pre-therapy interleukin-2 levels measured in 10 patients were normal or supranormal in 8, 6 of whom were treatment responders. Two patients with low interleukin-2 levels were nonresponders. Cyclosporine A can be used to induce a remission in relapsing nephrotic patients, and short-term cyclosporine A therapy does not produce nephrotoxicity.

Original languageEnglish
Pages (from-to)729-734
Number of pages6
JournalKidney International
Volume33
Issue number3
DOIs
Publication statusPublished - 1 Jan 1988
Externally publishedYes

Fingerprint

Nephrotic Syndrome
Cyclosporine
Interleukin-2
Therapeutics
Steroids
Chlorambucil
Life Tables
Proteinuria
Serum Albumin
Cyclophosphamide
Creatinine
Cell Count
Cholesterol
High Pressure Liquid Chromatography
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Tejani, A., Butt, K., Trachtman, H., Suthanthiran, M., Rosenthal, C. J., & Khawar, M. R. (1988). Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney International, 33(3), 729-734. https://doi.org/10.1038/ki.1988.59

Cyclosporine A induced remission of relapsing nephrotic syndrome in children. / Tejani, A.; Butt, K.; Trachtman, H.; Suthanthiran, Manikkam; Rosenthal, C. J.; Khawar, M. R.

In: Kidney International, Vol. 33, No. 3, 01.01.1988, p. 729-734.

Research output: Contribution to journalArticle

Tejani, A, Butt, K, Trachtman, H, Suthanthiran, M, Rosenthal, CJ & Khawar, MR 1988, 'Cyclosporine A induced remission of relapsing nephrotic syndrome in children', Kidney International, vol. 33, no. 3, pp. 729-734. https://doi.org/10.1038/ki.1988.59
Tejani, A. ; Butt, K. ; Trachtman, H. ; Suthanthiran, Manikkam ; Rosenthal, C. J. ; Khawar, M. R. / Cyclosporine A induced remission of relapsing nephrotic syndrome in children. In: Kidney International. 1988 ; Vol. 33, No. 3. pp. 729-734.
@article{aff19ae5ba234c7ab64310ca9fd654ce,
title = "Cyclosporine A induced remission of relapsing nephrotic syndrome in children",
abstract = "We treated 20, steroid resistant or steroid dependent and cyclophosphamide or chlorambucil treated, relapsing nephrotic patients with oral cyclosporine A for eight weeks. Cyclosporine A was started at 7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of 20 patients, 14 had a complete remission and the remaining 6 had a reduction in their proteinuria. The mean serum albumin of the 14 responders rose from 2.1 g/dl to 4.1 g/dl (P < 0.00001) after cyclosporine A therapy. The mean serum cholesterol of the 14 responders decreased from 394 mg/dl to 184 mg/dl (P < 0.0001) after cyclosporine A therapy. The mean creatinine clearance of the 20 patients (104 ml/min/1.73 m2) was unchanged (107 ml/min/1.73 m2) after eight weeks of cyclosporine A. By life table analysis, 40{\%} of the responders show a sustained remission of up to a year. Cyclosporine A responders had a higher T3 cell count prior to therapy compared to nonresponders (69 ± 5.54{\%} vs. 61 ± 6.4{\%}, P < 0.02). Pre-therapy interleukin-2 levels measured in 10 patients were normal or supranormal in 8, 6 of whom were treatment responders. Two patients with low interleukin-2 levels were nonresponders. Cyclosporine A can be used to induce a remission in relapsing nephrotic patients, and short-term cyclosporine A therapy does not produce nephrotoxicity.",
author = "A. Tejani and K. Butt and H. Trachtman and Manikkam Suthanthiran and Rosenthal, {C. J.} and Khawar, {M. R.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1038/ki.1988.59",
language = "English",
volume = "33",
pages = "729--734",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Cyclosporine A induced remission of relapsing nephrotic syndrome in children

AU - Tejani, A.

AU - Butt, K.

AU - Trachtman, H.

AU - Suthanthiran, Manikkam

AU - Rosenthal, C. J.

AU - Khawar, M. R.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We treated 20, steroid resistant or steroid dependent and cyclophosphamide or chlorambucil treated, relapsing nephrotic patients with oral cyclosporine A for eight weeks. Cyclosporine A was started at 7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of 20 patients, 14 had a complete remission and the remaining 6 had a reduction in their proteinuria. The mean serum albumin of the 14 responders rose from 2.1 g/dl to 4.1 g/dl (P < 0.00001) after cyclosporine A therapy. The mean serum cholesterol of the 14 responders decreased from 394 mg/dl to 184 mg/dl (P < 0.0001) after cyclosporine A therapy. The mean creatinine clearance of the 20 patients (104 ml/min/1.73 m2) was unchanged (107 ml/min/1.73 m2) after eight weeks of cyclosporine A. By life table analysis, 40% of the responders show a sustained remission of up to a year. Cyclosporine A responders had a higher T3 cell count prior to therapy compared to nonresponders (69 ± 5.54% vs. 61 ± 6.4%, P < 0.02). Pre-therapy interleukin-2 levels measured in 10 patients were normal or supranormal in 8, 6 of whom were treatment responders. Two patients with low interleukin-2 levels were nonresponders. Cyclosporine A can be used to induce a remission in relapsing nephrotic patients, and short-term cyclosporine A therapy does not produce nephrotoxicity.

AB - We treated 20, steroid resistant or steroid dependent and cyclophosphamide or chlorambucil treated, relapsing nephrotic patients with oral cyclosporine A for eight weeks. Cyclosporine A was started at 7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of 20 patients, 14 had a complete remission and the remaining 6 had a reduction in their proteinuria. The mean serum albumin of the 14 responders rose from 2.1 g/dl to 4.1 g/dl (P < 0.00001) after cyclosporine A therapy. The mean serum cholesterol of the 14 responders decreased from 394 mg/dl to 184 mg/dl (P < 0.0001) after cyclosporine A therapy. The mean creatinine clearance of the 20 patients (104 ml/min/1.73 m2) was unchanged (107 ml/min/1.73 m2) after eight weeks of cyclosporine A. By life table analysis, 40% of the responders show a sustained remission of up to a year. Cyclosporine A responders had a higher T3 cell count prior to therapy compared to nonresponders (69 ± 5.54% vs. 61 ± 6.4%, P < 0.02). Pre-therapy interleukin-2 levels measured in 10 patients were normal or supranormal in 8, 6 of whom were treatment responders. Two patients with low interleukin-2 levels were nonresponders. Cyclosporine A can be used to induce a remission in relapsing nephrotic patients, and short-term cyclosporine A therapy does not produce nephrotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0023850641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023850641&partnerID=8YFLogxK

U2 - 10.1038/ki.1988.59

DO - 10.1038/ki.1988.59

M3 - Article

C2 - 2966873

AN - SCOPUS:0023850641

VL - 33

SP - 729

EP - 734

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -